Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. by Akassoglou, K et al.
UCSF
UC San Francisco Previously Published Works
Title
Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration 
and demyelination after sciatic nerve injury.
Permalink
https://escholarship.org/uc/item/08h561gg
Journal
The Journal of cell biology, 149(5)
ISSN
0021-9525
Authors
Akassoglou, K
Kombrinck, KW
Degen, JL
et al.
Publication Date
2000-05-01
DOI
10.1083/jcb.149.5.1157
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
 ª
 
 The Rockefeller University Press, 0021-9525/2000/05/1157/10 $5.00
The Journal of Cell Biology, Volume 149, Number 5, May 29, 2000 1157–1166
http://www.jcb.org 1157
 
Tissue Plasminogen Activator–mediated Fibrinolysis Protects Against 
Axonal Degeneration and Demyelination after Sciatic Nerve Injury
 
Katerina Akassoglou,* Keith W. Kombrinck,
 
‡
 
 Jay L. Degen,
 
‡
 
 and Sidney Strickland*
 
*Department of Pharmacology, State University of New York at Stony Brook, Stony Brook, New York 11794-8651; and 
 
‡
 
Division of Developmental Biology, Children’s Hospital Research Foundation, Cincinnati, Ohio 45229
 
Abstract. 
 
 Tissue plasminogen activator (tPA) is a 
serine protease that converts plasminogen to plasmin 
and can trigger the degradation of extracellular matrix 
proteins. In the nervous system, under noninflamma-
tory conditions, tPA contributes to excitotoxic neuronal 
death, probably through degradation of laminin. To 
evaluate the contribution of extracellular proteolysis in 
inflammatory neuronal degeneration, we performed 
sciatic nerve injury in mice. Proteolytic activity was in-
creased in the nerve after injury, and this activity was 
primarily because of Schwann cell–produced tPA. To 
identify whether tPA release after nerve damage played 
a beneficial or deleterious role, we crushed the sciatic 
nerve of mice deficient for tPA. Axonal demyelination 
was exacerbated in the absence of tPA or plasminogen, 
indicating that tPA has a protective role in nerve injury, 
and that this protective effect is due to its proteolytic 
action on plasminogen. Axonal damage was correlated 
with increased fibrin(ogen) deposition, suggesting that 
this protein might play a role in neuronal injury. Consis-
tent with this idea, the increased axonal degeneration 
phenotype in tPA- or plasminogen-deficient mice was 
ameliorated by genetic or pharmacological depletion of 
fibrinogen, identifying fibrin as the plasmin substrate in 
the nervous system under inflammatory axonal dam-
age. This study shows that fibrin deposition exacerbates 
axonal injury, and that induction of an extracellular 
proteolytic cascade is a beneficial response of the tissue 
to remove fibrin. tPA/plasmin-mediated fibrinolysis 
may be a widespread protective mechanism in neuroin-
flammatory pathologies.
Key words: coagulation • extracellular matrix • an-
crod • Schwann cells • proteolysis
 
Introduction
 
The most common reaction of the nervous system after
disconnection of axons from the neuronal body is axon ly-
sis and myelin sheath fragmentation. These processes con-
tribute to functional impairment of the nerve. Axonal and
myelin damage are observed in a variety of nervous sys-
tem diseases with diverse etiologies, such as stroke (Saw-
lani et al., 1997), spongiform encephalopathies (Liberski
and Gajdusek, 1997), Guillan-Barre syndrome (Trojaborg,
1998), insulin-dependent diabetic neuropathy (Said et al.,
1992), and multiple sclerosis (Trapp et al., 1998; Arnold,
1999). In these diseases, axonal degeneration is considered
to be responsible for permanent disability. It has been pro-
posed that proteases such as plasminogen activators
(Reich, 1978; Tsirka et al., 1995; Seeds et al., 1997) and
matrix metalloproteinases (LaFleur et al., 1996) may play
a role in nervous system damage.
Plasminogen activators (PAs)
 
1
 
 are serine proteases,
which convert plasminogen to plasmin. Plasmin is a po-
tent serine protease that can degrade a variety of pro-
teins, but its primary substrate in vivo is fibrin, the pro-
teinaceous component of blood clots (Bugge et al., 1996).
There are two PAs identified in mammals: tissue-type and
urokinase-type. The PA/plasmin system can have delete-
rious effects in pathological settings via proteolysis of tis-
sue proteins. For example, plasmin-catalyzed degradation
of laminin promotes excitotoxic-mediated neurodegener-
ation in the hippocampus (Chen and Strickland, 1997),
and plasmin can also degrade myelin basic protein (MBP)
in vitro (Cammer et al., 1978; Norton et al., 1990). Con-
versely, the PA/plasmin system can be beneficial via its fi-
brinolytic activity, since PA/plasmin-mediated proteolysis
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Abbreviations used in this paper: 
 
ECM, extracellular matrix; fib, fi-
brin(ogen); MBP, myelin basic protein; PA, plasminogen activator; PAI-1,
plasminogen activator inhibitor-1; plg, plasminogen; PNS, peripheral ner-
vous system; tPA, tissue plasminogen activator; uPA, urokinase plasmino-
gen activator.
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plays a critical role in fibrin(ogen) clearance (Bugge et al.,
1996).
In experimental nerve injury (Bignami et al., 1982;
Sallés et al., 1990), as well as in human neuroinflammatory
diseases such as multiple sclerosis, PAs and their inhibi-
tors can be upregulated (Akenami et al., 1997, 1999;
Cuzner and Opdenakker, 1999). However, it is not clear if
this altered expression is deleterious or a beneficial re-
sponse of the tissue to the disease. In the current study, we
sought to investigate how PAs affect degeneration severity
in the peripheral nervous system (PNS) in vivo. To this
end, we performed sciatic nerve injury experiments in
mice genetically deficient for tPA (Carmeliet et al., 1994),
plasminogen (Bugge et al., 1995; Ploplis et al., 1995), and
fibrinogen (Suh et al., 1995). Nerve crush in the PNS is a
reliable experimental model that allows the study of ax-
onal degeneration (Bridge et al., 1994). Our analysis re-
vealed induction of tPA expression after nerve injury. Ax-
onal and myelin loss were exacerbated in tPA- and
plasminogen-deficient mice, whereas fibrinogen depletion
was protective. Fibrin deposition was also correlated with
nerve damage. These results demonstrate that tPA/plas-
min-catalyzed fibrin degradation can protect neurons against
axonal injury at least in the PNS.
 
Materials and Methods
 
Animals
 
tPA-deficient mice (tPA
 
2
 
/
 
2
 
) (Carmeliet et al., 1994) have been back-
crossed to C57Bl/6J for nine generations. Urokinase plasminogen activa-
tor (uPA)-deficient mice (uPA
 
2
 
/
 
2
 
) (Carmeliet et al., 1994) also have been
backcrossed to the C57Bl/6J background. C57Bl/6 mice were used as wild-
type controls. Plg-deficient mice (plg
 
2
 
/
 
2
 
) (Bugge et al., 1995), which are
heterozygous for fib deficiency, fibrinogen-deficient mice (fib
 
2
 
/
 
2
 
) (Suh et
al., 1995), which are heterozygous for plg deficiency; and combined plg-,
fibrinogen-deficient mice (plg
 
2
 
/
 
2
 
fib
 
2
 
/
 
2
 
) were of mixed genetic back-
ground. Heterozygous plg
 
1
 
/
 
2
 
fib
 
1
 
/
 
2
 
 littermates were employed as controls
in all studies. No differences were observed between C57Bl/6J mice and
heterozygous plg
 
1
 
/
 
2
 
fib
 
1
 
/
 
2
 
 mice in the crush injury model. All mice were
8–15-wk old at the start of the experiment. The genotype of all mice was
confirmed at the end of the experiments by PCR analysis of genomic
DNA extracted from mice tails. All experiments were performed in com-
pliance with institutional guidelines.
 
Sciatic Nerve Crush Injury
 
Adult mice were anesthetized by intraperitoneal injection of 2.5% avertin
(0.18 ml/10 g body weight; Aldrich Chemical Co.). For the crush injury,
sciatic nerves were crushed midthigh three times (20 s each) with watch-
maker’s forceps, the tips of which had been previously cooled in liquid ni-
trogen (Funakoshi et al., 1998). The crush site was marked with India ink
(LaFleur et al., 1996). Skin incisions were closed with sutures.
 
PA In Situ Zymography
 
For in situ zymographies (Sappino et al., 1993), 10-
 
m
 
m unfixed, cryostat
sciatic nerve sections were prepared. Sections were covered by a casein
overlay containing 1% low melting point agarose and 25 
 
m
 
g/ml plasmino-
gen, and covered with a coverslip. Plasminogen was prepared from human
plasma (Deutsch and Mertz, 1970). Control experiments were performed
with overlay mixtures lacking plasminogen. To distinguish uPA from tPA
activity, amiloride (Sigma Chemical Co.), a specific inhibitor of uPA enzy-
matic activity (Vassalli and Belin, 1987), was added in the mixture at 1
mM final concentration. To discriminate between tPA and other fibrino-
lytic enzymes, tPA-STOP (2,7-bis-(4-amidinobenzylidene)-cycloheptan-
1-one dihydrochloride salt; American Diagnostica) at a concentration of
50 
 
m
 
g/ml was used. Sections were incubated at room temperature in a hu-
midified chamber. Conversion of plasminogen into plasmin, which in turn
lysed the insoluble casein, resulted in the appearance of lytic zones within
 
6 h. Zones of plasmin-dependent caseinolysis appeared as black areas
when photographed under darkfield illumination.
 
Immunohistochemistry and Immunoblot Analysis
 
Dissected nerves were embedded in Tissue-Tek OCT, then immediately
frozen on dry ice and stored at 
 
2
 
70
 
8
 
C until use. Sections were cut longitu-
dinally on a motor-driven Leica cryostat with a retraction microtome and
a steel knife at a cabinet temperature of 
 
2
 
20
 
8
 
C.
Immunohistochemical staining was performed on cryostat sections
(Akassoglou et al., 1997, 1998). Primary antibodies were as follows: rabbit
anti-human tPA (1:1,200; Waller and Schleuning, 1985), goat anti–human
fibrin(ogen) (1:500; Chemicon International, Inc.), rabbit anti–cow GFAP
(1:200; Dako), rabbit anti–mouse laminin (1:1,000; Sigma Chemical Co.),
rabbit anti–mouse fibronectin (1:200; Chemicon International, Inc.), rat
anti–mouse VCAM-1 (Chemicon International, Inc., 1:50), rabbit anti–
human MBP (1:200; DAKO), sheep anti–mouse PA inhibitor 1 (PAI-1)
(1:200; American Diagnostica), and rabbit antineuroserpin (1:2,000; pro-
vided by D. Lawrence, Department of Vascular Biology, American Red
Cross Holland Laboratory, Rockville, MD). Bound antibodies were visu-
alized using either the avidin–biotin-peroxidase complex (Vectastain Elite
ABC kit; Vector Laboratories) and 3-amino-9-ethylcarbazole (Sigma
Chemical Co.) as a chromogen, or the avidin–biotin-alkaline phosphatase
complex (Vectastain Elite ABC kit; Vector Laboratories), using nitroblue
tetrazolium/brom-chlor-indolyl phosphate (Vector Laboratories). Stain-
ing specificity for the tPA and fibrin(ogen) antibodies was confirmed us-
ing tissue from tPA
 
2
 
/
 
2
 
 and fib
 
2
 
/
 
2
 
 mice, respectively. Staining specificity
for GFAP antibody was confirmed using rabbit IgG. Incubation without
the primary antibody served as a negative control. Histochemical Oil Red
O staining, which stains lipids and reveals demyelinated areas (Akas-
soglou et al., 1997), was performed on cryostat sections. Immunoblot for
neuroserpin was performed on sciatic nerve extracts as described in Has-
tings et al., 1997.
 
Quantification of Axonal Degeneration
 
8 d after injury, animals were intracardially perfused under deep anesthe-
sia with ice-cold 2% paraformaldehyde, and 0.5% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.2, for 1 min followed by ice-cold 3% glutaralde-
hyde in 0.1 M phosphate buffer for 5 min. The injured sciatic nerve was re-
moved, and the region 
 
z
 
5 mm below the injury site (crush site marked
with India ink) was isolated. The noninjured sciatic nerve (contralateral)
served as a control. Nerves were immersion fixed for 24 h in phosphate-
buffered 3% glutaraldehyde, postfixed in 2% osmium tetroxide solution,
and embedded in resin. Semi-thin sections were cut on an Ultra-cut micro-
tome and stained with toluidine blue. A morphometric grid (100 mm
 
2
 
)
was adapted to the microscope, and a minimum of three grids per sample
of myelinated axons was counted.
 
Systemic Defibrinogenation
 
Mice were depleted of fibrinogen as described in Busso et al. (1998). In
brief, mice were anesthetized, their backs shaved, and 14-d mini-osmotic
pumps (model 2002; Alza Corp.) filled with a solution of 250 U ancrod per
ml of 0.1 M NaCl and 0.1 M Tris-HCl, pH 7.5 (Sigma Chemical Co.) were
implanted subcutaneously into their backs (one mini-pump per animal).
The insertion sites were closed by sutures. The pumps deliver 0.5 
 
m
 
l/h, so
the mice received 3 U ancrod/d. In control animals, buffer-filled mini-
pumps were implanted. On day 3 of ancrod infusion, sciatic nerve crush or
transection was performed. 8 d after the crush, mice were killed, and tis-
sues were prepared for cryostat or semi-thin sections.
 
Quantification of Muscle Atrophy
 
8 d after injury, animals were killed, the skeletal muscles from the injured
(ipsilateral) and the control (contralateral) site were isolated, and their
net weight was calculated. The percentage of atrophy was determined for
each animal by subtracting the weight of the muscle from the injured site
from the weight of the muscle of the control site. The difference was mul-
tiplied by 100 and divided by the muscle weight of the control site.
 
Results
 
tPA Is the Major PA Induced after Sciatic Nerve Injury
 
Plasminogen activator activity (Bignami et al., 1982) and
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tPA mRNA (Yuguchi et al., 1997) and protein (Neuberger
and Cornbrooks, 1989) expression are increased in the
PNS after injury. To address the major type of PA induced
after injury, we performed in situ zymography on sciatic
nerves of wild-type, tPA
 
2
 
/
 
2
 
, and uPA
 
2
 
/
 
2
 
 mice. When com-
pared with control uninjured nerve (Fig. 1 A), wild-type
sciatic nerve 8 d after crush showed an induction of pro-
teolytic activity (Fig. 1 B, dark zone around nerve). Wild-
type control or injured sciatic nerves incubated with an
overlay that lacked plasminogen did not show any pro-
teolytic activity (data not shown), indicating that the ac-
tivity was plasminogen-dependent. tPA
 
2
 
/
 
2
 
-injured sciatic
nerve did not show appreciable proteolytic activity (Fig. 1
C), whereas uPA
 
2
 
/
 
2
 
-injured sciatic nerve showed an in-
duction of proteolytic activity (Fig. 1 D) similar to the in-
jured wild-type control (Fig. 1 B). Addition of tPA-STOP,
a specific tPA inhibitor, blocked the activity (Fig. 1 E),
whereas addition of amiloride, a specific inhibitor of uPA
proteolytic activity, had no effect (Fig. 1 F). After 24 h of
assay, a lytic zone started to appear in wild-type sciatic
nerves in the presence of tPA-STOP as well as in the
tPA
 
2
 
/
 
2
 
 crushed sciatic nerves (data not shown), suggesting
the presence of low uPA activity. These results show that
the proteolytic activity induced after sciatic nerve injury is
mainly due to tPA.
 
tPA Is Expressed by Schwann Cells after Sciatic
Nerve Injury
 
Tissue plasminogen activator has been shown to be pro-
duced by Schwann cells and the growth cones of periph-
eral neurons in culture (Krystosek and Seeds, 1984; Clark
et al., 1991). To identify the cellular localization of tPA
protein in vivo, sciatic nerves before and after crush were
stained with an antibody against tPA. When compared
 
with the uninjured sciatic nerve (Fig. 2 A), immunoreac-
tivity specific for tPA was increased as early as 2 d after
the crush (Fig. 2 B). The lack of staining in the tPA
 
2
 
/
 
2
 
 sci-
atic nerve with the anti-tPA antibody (Fig. 2 C) showed
that the antibody was specific. Staining of parallel sections
showed that the tPA immunoreactive cells (Fig. 2 D) had
similar morphology to cells positive for GFAP (Fig. 2 E), a
Schwann cell marker. In contrast, immunostaining with an
antibody against Mac-1, a macrophage-specific marker,
showed a different staining pattern than that for tPA (data
not shown). These results suggest Schwann cells as a major
source of tPA in the sciatic nerve after injury.
To examine the possible role of endogenous inhibitors
of tPA, we analyzed the expression of PAI-1 and neuro-
serpin in the sciatic nerve before and after injury. Immu-
nostaining for PAI-1 revealed that there was no PAI-1
expression before or after injury (data not shown). Neu-
roserpin, a brain-associated inhibitor of tPA (Osterwalder
et al., 1996; Hastings et al., 1997), is constitutively ex-
pressed in the sciatic nerve (Lawrence, D., personal com-
munication). Western blot analysis and immunohis-
tochemistry on wild-type and tPA
 
2
 
/
 
2
 
 sciatic nerve extracts
did not reveal any significant increase of neuroserpin after
injury (data not shown). Overall, these data suggest that
elevated tPA activity is due primarily to increased expres-
sion of the protein, and not to downregulation of protease
inhibitors.
 
Exacerbation of Axonal Degeneration in tPA
 
2
 
/
 
2
 
 and 
plg
 
2
 
/
 
2
 
 Mice
 
Since tPA is the major PA produced after sciatic nerve in-
jury, we compared lesion formation after sciatic nerve
crush in wild-type and tPA
 
2
 
/
 
2
 
 mice. Toluidine blue stain-
ing for myelin in semi-thin cross-sections of crushed
Figure 1. tPA is the major PA induced after sci-
atic nerve injury. In situ zymography to detect
proteolytic activity 8 d after crush (cd8) showed a
small proteolytic zone on wild-type uninjured sci-
atic nerve (A) and an increase of activity after in-
jury (B, dark zone around nerve). C–E show
nerves after injury. tPA2/2 sciatic nerve (C) did
not show any activity, whereas uPA2/2 nerve (D)
showed proteolytic activity similar to the wild
type (B). Proteolytic activity of wild-type sciatic
nerve was inhibited by tPA-STOP (E), a tPA in-
hibitor, but was unaffected by amiloride (F), a
uPA inhibitor. Assay time was 6 h. Bar, 1 mm.
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nerves after 8 d showed a dramatic decrease in myelinated
axons in tPA
 
2
 
/
 
2
 
 mice (Fig. 3 D), when compared with
wild-type mice (Fig. 3 C). Similarly, light microscopy anal-
ysis of the lesion at 8 d with Oil Red O, which stains the
lipids associated with the myelin sheath, revealed in-
creased myelin debris in tPA
 
2
 
/
 
2
 
 mice (Fig. 3 F, aggregates
of lipid), when compared with wild-type controls (Fig. 3
E). To examine whether the difference in demyelinating
damage persisted at later times, we analyzed sciatic nerves
22 d after crush. Since at later times the myelin and axonal
debris has been removed, Oil Red O staining is not infor-
mative. Therefore, tissue morphology was examined with
an antibody against MBP, which stains myelinated axons.
In accordance with our observation 8 d after the crush,
tPA
 
2
 
/
 
2
 
 mice had decreased immunoreactivity for MBP
(Fig. 3 H), when compared with wild-type controls (Fig. 3
G). This result shows that, at later times after crush injury,
there are fewer myelinated axons in tPA
 
2
 
/
 
2
 
 mice than in
wild-type mice.
To quantitate the effect of tPA on axonal demyelina-
tion, we counted myelinated axons in semi-thin sections.
This quantification showed (myelinated axons/0.1 mm
 
2
 
)
the following: 10.3 
 
6 
 
2.4 in control, and 2.1 
 
6 
 
0.3 in tPA
 
2
 
/
 
2
 
(Fig. 4 D). The decrease in the number of myelinated ax-
ons in tPA
 
2
 
/
 
2
 
 mice compared with control mice was statis-
tically significant (
 
P
 
 , 
 
0.01).
To assess whether the increase in axonal degeneration
in the absence of tPA was due to its proteolytic function,
we performed crush injury in mice genetically deficient for
plasminogen, which is the primary substrate for tPA. Plg
 
2
 
/
 
2
 
mice (Fig. 4 A) showed a similar reduction in myelinated
axons as tPA
 
2
 
/
 
2
 
 mice (Fig. 3 F). Quantification of myelin-
ated axons/0.1 mm
 
2
 
 showed 2.8 
 
6 
 
0.7 in plg
 
2
 
/
 
2
 
 (Fig. 4 D).
The decrease in myelinated axons in plg
 
2
 
/
 
2
 
 mice com-
pared with control mice was statistically significant (
 
P
 
 ,
 
0.02), and there was no significant difference between tPA
and plg
 
2
 
/
 
2
 
 mice. These results indicate that tPA reduces
axonal loss and demyelination in the PNS primarily
through its proteolytic effect on plasminogen. These re-
sults do not exclude a subtle nonproteolytic effect of tPA,
as has been observed in other systems (Kim et al., 1999;
Rogove et al., 1999).
 
Loss of Fibrinogen Rescues Exacerbation of Axonal 
Degeneration Observed in plg
 
2
 
/
 
2
 
 Mice
 
Removal of fibrinogen rescues mice from most of the ef-
fects of plasminogen deficiency (Bugge et al., 1996). How-
ever, the resistance of plasminogen-deficient mice to exci-
totoxic neuronal degeneration in the hippocampus is not
affected by the removal of fibrinogen (Tsirka et al., 1997a).
To determine if fibrin(ogen) was playing a role in inflam-
matory neuronal degeneration, we performed nerve crush
in mice with fibrinogen deficiency (fib
 
2
 
/
 
2
 
) or a double de-
ficiency for plasminogen and fibrinogen. Fib
 
2
 
/
 
2
 
 mice were
similar to wild-type mice in myelinated axons (Fig. 4, B
and D). The decrease in myelinated axons observed in
plg
 
2
 
/
 
2
 
 mice (Fig. 4 A) was alleviated by genetically super-
imposing fibrinogen deficiency (plg
 
2
 
/
 
2
 
fib
 
2
 
/
 
2
 
; Fig. 4, C and
D). These results indicate that tPA/plasmin-mediated deg-
Figure 2. tPA is produced by
Schwann cells after sciatic
nerve crush. Immunocy-
tochemistry with an antibody
against tPA on longitudinal
cryostat sections of wild-type,
uninjured sciatic nerve re-
vealed tPA staining only of
the sciatic nerve vasculature
(A). As early as 2 d after
crush (cd2) tPA immunore-
activity was increased in the
endoneurium (B). Sciatic
nerve from a tPA2/2 mouse
showed no immunoreactivity
with the tPA antibody (C).
Immunostaining of parallel
sections of a wild-type sciatic
nerve 2 d after crush showed
similar morphology between
tPA immunoreactive cells
(D) and GFAP-positive
Schwann cells (E). The num-
ber of GFAP-positive cells
was equivalent in wild-type
and tPA2/2 nerves before and
after crush, suggesting that
the number of Schwann cells
is not significantly different
in the two genotypes. Bar:
(A–C) 93 mm; (D–E) 18 mm.
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radation of fibrin(ogen) protects axons from degeneration
and demyelination. Quantification of myelinated axons/
0.1 mm
 
2
 
 showed the following: 12.0 
 
6 
 
2.8 in fib
 
2
 
/
 
2
 
, and
15.2 
 
6 
 
4.0 in plg
 
2
 
/
 
2
 
fib
 
2
 
/
 
2
 
 (Fig. 4 D). The increase in the
number of myelinated axons in the plg
 
2
 
/
 
2
 
fib
 
2
 
/
 
2
 
 mice
compared with the plg
 
2
 
/
 
2
 
 mice was statistically significant
(
 
P
 
 , 
 
0.03).
 
Fibrin(ogen) Deposition Increases after Nerve Injury 
and Correlates with Axonal Degeneration
 
To address the involvement of fibrin(ogen) in axonal de-
generation and myelin loss, we performed immunocyto-
chemistry with an antibody against fibrin(ogen). A partial
nerve crush at the sciatic nerve revealed that the crushed
part of the nerve, which underwent degeneration (Fig. 5
A), had extensive deposition of fibrin(ogen), whereas the
immediately adjacent, uninjured region was free of fi-
brin(ogen) (Fig. 5 B). Absence of staining of a fib
 
2
 
/
 
2
 
 sci-
atic nerve documented the specificity of the antibody
against fibrin(ogen) (not shown). This staining indicates
that fibrin(ogen) deposition is spatially correlated with de-
generation.
We also examined other extracellular matrix (ECM) pro-
teins for their involvement in sciatic nerve injury. In the
mouse hippocampus, tPA-mediated degradation of lami-
Figure 3. Axonal degenera-
tion and demyelination are
exacerbated in tPA-deficient
mice after sciatic nerve
crush. Oil Red O staining of
cryostat sections of uninjured
wild-type sciatic nerve (A)
revealed normal myelin dis-
tribution, and toluidine blue
staining of sciatic nerve semi-
thin cross-sections showed
normal axon morphology
(B). 8 d after crush (cd8),
toluidine blue staining of
semi-thin cross-sections of
wild-type mice (C) demon-
strated more myelinated ax-
ons (arrows) than tPA2/2
mice (D). Oil Red O staining
showed increased accumula-
tion of myelin and lipid de-
bris in the tPA2/2 (F) com-
pared with the wild-type (E)
sciatic nerve. 22 d after crush
(cd22), staining for myelin
basic protein revealed fewer
myelinated axons in tPA2/2
(H) than in wild-type (G)
nerves. Bar, 18 mm.
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nin after injury is implicated in neurodegeneration (Chen
and Strickland, 1997). To examine the expression pattern
of laminin in sciatic nerve injury, we stained sciatic nerves
before and after crush with an antibody against laminin.
Laminin was expressed in the normal and the tPA2/2 sci-
atic nerve, and this expression was not significantly altered
after injury (data not shown). Another ECM protein, fi-
bronectin, was equally expressed at low levels in wild-type
and tPA2/2 sciatic nerves, and not altered by injury. To ex-
amine if differences in adhesion molecules could contrib-
ute to the exacerbated phenotype observed in tPA2/2
mice, we stained wild-type and tPA2/2 mice for VCAM-1,
which is upregulated after injury (Castano et al., 1996).
Wild-type and tPA2/2 mice showed similar upregulation
of VCAM-1 after crush. These results suggest that lami-
nin, fibronectin, and VCAM-1 do not contribute to the al-
tered peripheral nerve phenotype of tPA2/2 mice.
Pharmacological Depletion of Fibrin(ogen) Protects 
Mice from Axonal Degeneration
Administration of ancrod, a Malayan pit viper (Callose-
lasma rhodostoma) venom protein, leads to consumption
of systemic fibrinogen and drastically reduces plasma fi-
brinogen levels (Bell et al., 1978). Therefore, under these
conditions, excessive fibrin deposition should be dimin-
ished, which might result in less nerve damage. Ancrod
(3 U/d) was administered to tPA2/2 mice for 3 d before
crush, and then throughout the experimental period, with-
out any effects on survival. tPA2/2 mice treated with an-
crod showed dramatically reduced fibrin(ogen) immu-
noreactivity (Fig. 6 B) when compared with untreated tPA
mice (Fig. 6 A).
Histopathological analysis revealed that depletion of fi-
brin(ogen) rescued tPA2/2 mice from exacerbated axonal
degeneration. tPA2/2 mice treated with ancrod showed
more myelinated axons (Fig. 6 D) when compared with
untreated tPA2/2 mice (Fig. 6 C). Quantification of my-
elinated axons/0.1 mm2 showed the following: 2.1 6 0.3 in
tPA2/2, and 5.9 6 0.6 in tPA2/2 treated with ancrod (Fig. 6
E). The increase in myelinated axons in the tPA2/2 mice
treated with ancrod compared with the untreated tPA2/2
mice was statistically significant (P , 0.01).
Although we detected no morphological differences
in the uninjured sciatic nerves of the various mouse ge-
notypes, the possibility existed that subtle anatomical
changes due to gene disruption might be playing a role in
the phenotype. The ancrod experiment is important in
eliminating this possibility. Since the tPA2/2 mice used
were highly inbred and, therefore, genetically identical,
the reversal of the phenotype by fibrinogen depletion indi-
cates that acute fibrin deposition is responsible for exacer-
bating the nerve damage in the tPA2/2 mice.
Muscle Atrophy after Nerve Injury Is Decreased after 
Fibrin(ogen) Depletion
To assess a possible functional consequence of fibrin(ogen)
depletion, we examined skeletal muscle weight decay after
nerve crush. The gastrocnemius muscle atrophies after sci-
atic nerve injury due to muscle denervation and the per-
centage of atrophy corresponds to the degree of nerve
Figure 4. tPA protects from
axonal degeneration through
a proteolytic mechanism.
Toluidine blue staining of sci-
atic nerve semi-thin cross-
sections of plg2/2 mice (A)
reveals exacerbated axonal
damage. Fib2/2 mice (B) and
plg2/2fib2/2 (C) mice showed
myelinated axons similar in
number to wild-type mice
(C). (D) Quantification of
myelinated axons. First col-
umn shows uninjured sciatic
nerve (n 5 4). After crush,
tPA2/2 (n 5 6) and plg2/2
(n 5 4) nerves showed signif-
icantly fewer myelinated ax-
ons compared with control
injured nerve (n 5 5) (P ,
0.01 and P , 0.04, respec-
tively). Crushed fib2/2 (n 5
7) and plg2/2fib2/2 (n 5 4)
nerves showed the same
number of axons as control
crushed nerves. Plg2/2fib2/2
nerves showed more myelin-
ated axons compared with
tPA2/2 nerves (P , 0.04).
Uninjured sciatic nerves from all genotypes had similar number of myelinated axons and similar morphology. Data are expressed as
means 6 SEM. Statistical comparisons between medians were made with the t test. Scale as in Fig. 3.
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damage (Funakoshi et al., 1998). Therefore, a direct mea-
sure of functional impairment can be obtained by assess-
ing muscle weight (Fig. 7). Muscle mass of wild-type mice
dropped 24.5 6 2.7% 8 d after the sciatic nerve crush com-
pared with the unlesioned, contralateral side. Exacerba-
tion of muscle mass atrophy in the tPA2/2 mice 8 d after
crush (40.1 6 3.8%; P , 0.005 compared with wild-type
mice) indicated increased axonal damage in the absence of
tPA. 22 d after crush, muscle atrophy was 81% for a tPA2/2
mouse, whereas for a wild-type mouse it was 66%. This
preliminary evidence suggests that increased muscle atro-
phy persists at later time points after injury. After treat-
ment with ancrod, there was less muscle atrophy in tPA2/2
mice (16.6 6 3.4%). The decrease in muscle mass atrophy
in the ancrod-treated tPA2/2 mice compared with the un-
treated tPA2/2 was statistically significant (P , 0.001).
This observation agrees with the histopathological obser-
vation that depletion of fibrin(ogen) protects tPA2/2 mice
from exacerbated axonal damage. Overall, these results
suggest that tPA-mediated fibrinolysis protects motor ax-
ons after nerve injury.
Discussion
The studies reported here demonstrate that upregulation
of tPA and plasmin is beneficial in reducing axonal dam-
age; fibrin(ogen) deposition correlates with axonal de-
generation; and depletion of fibrin(ogen) rescues mice
from exacerbated axonal damage. These results indicate
that plasmin-mediated removal of fibrin(ogen) deposits is
critical for limiting axonal degeneration and demyelina-
tion.
Figure 5. Fibrin(ogen) deposition increases after sciatic nerve in-
jury and correlates with axonal degeneration and demyelination.
Staining of parallel sections of a partially crushed wild-type sci-
atic nerve 8 d after injury with Oil Red O (A), a myelin stain, and
antifibrinogen antibody (B) revealed that the crushed part of the
nerve, which underwent axonal degeneration (A, Oil Red O
stained aggregates represent myelin debris accumulation), also
had extensive deposition of fibrin(ogen) (B), whereas the imme-
diately adjacent, uninjured region was free of fibrin(ogen). Dou-
ble-headed arrows indicate uninjured and crushed regions. Bar,
165 mm.
Figure 6. Pharmacological depletion of fibrin(ogen) reduces ax-
onal damage in tPA2/2 mice. Immunostaining for fibrin(ogen) re-
vealed deposition of fibrin(ogen) in tPA2/2 (A) mice, whereas
ancrod-treated tPA2/2 (B) mice showed little fibrin(ogen) immu-
noreactivity. Toluidine blue staining of semi-thin cross-sections
of crushed sciatic nerve (8 d after injury) of tPA2/2 mice treated
with ancrod showed an increase of myelinated axons (D) com-
pared with buffer-treated tPA2/2 mice (C). (E) Quantification of
myelinated axons 8 d after sciatic nerve crush. tPA2/2 mice
treated with ancrod (n 5 4) showed significantly more myelin-
ated axons than buffer-treated tPA2/2 mice (n 5 6, P , 0.01).
The difference between tPA2/2 mice treated with ancrod and
wild-type controls (n 5 5) was not statistically significant (ns).
Data are expressed as means 6 SEM. Statistical comparisons be-
tween medians were made with the t test. Bar: (A and B) 113 mm;
(C and D) 22 mm.
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Plasmin Can Be Beneficial or Pathogenic for Neuronal 
Degeneration Depending on Its Substrate
tPA2/2 (Tsirka et al., 1995) and plg2/2 (Tsirka et al., 1997b)
mice are resistant to excitotoxin-induced neuronal death
in the hippocampus, indicating that a tPA/plasmin pro-
teolytic cascade promotes neuronal degeneration under
these conditions. In this model of neuronal death, fib defi-
ciency does not affect the neurodegeneration-resistant
phenotype of the plg2/2 mice (Tsirka et al., 1997a), demon-
strating that fibrin is not the primary substrate for plasmin
in the hippocampus. Further experiments indicated that a
major plasmin substrate in the hippocampus is laminin
(Chen and Strickland, 1997). In contrast, after sciatic
nerve crush, exacerbation of axonal degeneration and de-
myelination observed in tPA2/2 and plg2/2 mice is rescued
in the absence of fibrinogen, showing that fibrin(ogen) is
the primary plasmin substrate during axonal degeneration
and demyelination under inflammatory conditions.
A difference between excitotoxic neuronal death and in-
flammatory axonal degeneration is the participation of se-
rum proteins in lesion formation. After excitotoxin injec-
tion, blood-brain barrier breakdown does not appear to
contribute to excitotoxic neuronal damage (Chen et al.,
1999). In contrast, under inflammatory conditions, disrup-
tion of the blood–brain barrier and fibrin deposition are
early expressions of immune effector activity and precede
clinical signs and axonal degeneration (Bush et al., 1993).
Neuronal death in the PNS is also often associated with
enhanced vascular permeability of the blood–nerve barrier
(Koh et al., 1993). A preliminary examination of blood–
nerve barrier disruption by IgG immunostaining revealed
no difference between wild-type and tPA2/2 mice (data
not shown).
The present findings, coupled with previous results
(Wang et al., 1998; Nagai et al., 1999; Kilic et al., 1999), re-
veal that a specific proteolytic system (e.g., tPA/plasmin)
can be either deleterious or beneficial after different chal-
lenges to the nervous system. The significant distinction as
to whether plasmin-mediated proteolysis is beneficial or a
liability may be the component(s) of the ECM targeted.
More specifically, plasmin degradation of fibrin may be
advantageous, whereas excessive plasmin-mediated degra-
dation of other matrix components may be associated with
pathologic manifestations.
Fibrin Deposition as a Contributor to
Axonal Degeneration
How does fibrin(ogen) deposition contribute to axonal
damage? Fibrin(ogen) is necessary for various inflamma-
tory responses in vivo (McRitchie et al., 1991; Tang and
Eaton, 1993), and deficiency in fibrinolysis can contribute
to pathogenic processes (Idell et al., 1989; Bugge et al.,
1996; Kitching et al., 1997; Busso et al., 1998; Drew et al.,
1998). Fibrin deposition also has been reported in multiple
sclerosis, where it has been shown to correlate with demy-
elinated plaques (Claudio et al., 1995).
Fibrin is deposited after injury in both wild-type and
tPA2/2 mice. Fibrin depletion improves the degeneration
phenotype of tPA2/2 or plasminogen2/2 mice, but not
wild-type mice. Further experiments may reveal subtle
quantitative or spatial aspects of fibrin deposition that can
explain why tPA2/2 mice have increased damage.
Persistent fibrin(ogen) deposition might affect axonal
degeneration by influencing inflammation, with conse-
quent aggravation of the injury. Local matrices may drive
the inflammatory response by providing a temporary scaf-
fold for inflammatory cell adhesion and migration and by
increasing chemotaxis at sites of inflammation (Tang and
Eaton, 1993). However, analysis of the inflammatory pro-
file of the sciatic nerve lesions did not reveal any major
differences in the macrophage or T cell number between
wild-type, tPA2/2, and systematically defibrinogenated
wild-type mice 8 d after injury (Akassoglou, K., and S.
Strickland, unpublished observations).
The plasmin/fibrin axis could also contribute to inflam-
mation by upregulation of proinflammatory cytokines. Cy-
tokines regulate the balance between proteases and their
inhibitors, and proteolysis can modulate cytokine activity
(Cuzner and Opdenakker, 1999). Interestingly, fibrin up-
regulates interleukin 1 (Perez and Roman, 1995) and tumor
necrosis factor (Formica et al., 1994), two pro-inflamma-
tory cytokines which are involved in inflammatory axonal
damage and demyelination in both the peripheral (Cre-
ange et al., 1997) and central nervous system (Akassoglou
et al., 1998; Wiemann et al., 1998). A more detailed
analysis of the inflammatory response and cytokine ex-
pression after injury may reveal an immunoregulatory role
for fibrin(ogen) in axonal damage and demyelination.
Our results suggest that tPA/plasmin-mediated fibrino-
lysis reduces axonal damage and, therefore, components of
this pathway might be used as a new approach to protect
axons from injury. In situations of chronic demyelination,
a large percentage of the damage might occur via a fibrin-
mediated pathway. In this case, depletion of fibrin(ogen)
or prevention of fibrin(ogen) deposition might protect
against demyelination. This approach would be especially
valuable if it could be accomplished locally at the site of
inflammation. Thus, the identification of fibrin(ogen) de-
Figure 7. Depletion of fibrin(ogen) reduces muscle atrophy.
Muscle atrophy 8 d after sciatic nerve crush was increased in the
absence of tPA and decreased after fibrinogen depletion. Muscle
mass in wild-type mice (n 5 7) dropped 24.5 6 2.7% compared
with the unlesioned, contralateral side, whereas in tPA2/2 mice
(n 5 7), muscle mass dropped 40.1 6 3.8% (P , 0.005 compared
with wild-type mice). After depletion of fibrinogen, muscle mass
in tPA2/2 mice treated with ancrod (n 5 5) muscle mass dropped
16.6 6 3.4% (P , 0.001 compared with tPA2/2 mice). Data are
expressed as means 6 SEM. Statistical comparisons between me-
dians were made with the t test.
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position as a new contributing factor to axonal degenera-
tion may yield additional strategies to prevent damage in
the nervous system.
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